Binge drinking decreases weekend adherence in a RCT from low and middle income countries

Similar documents
HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression

Immunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052

Evolving Realities of HIV Treatment in Resource-limited Settings

Psychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir

Adherence to ART in HIV-infected children in Kenya, South Africa, and Thailand

Alcohol s Impact on HIV Incidence, Treatment Adherence, and Health Outcomes

DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone

Central Nervous System Penetration of ARVs: Does it Matter?

HPTN 052. Myron S. Cohen, MD Principal Investigator. Presented at the 6 th Int. Workshop on HIV Transmission, July 2011, Rome, Italy

Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment

1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London

Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

Factors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa

Frailty and the Risk of Falls in HIV- Infected Older Adults in the ACTG A5322 Study

Adherence and HIV Suppression after Behavioral Intervention in Patients with Elevated Viral Load

CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries. The case against Di Gibb

Integrase Strand Transfer Inhibitors on the Horizon

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Second and third line paediatric ART strategies

Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens

The Open Label Trial Past and Present

D. Gillespie, K. Hood, A. Williams, R. Stenson, C.S.J. Probert and A.B. Hawthorne Clinical Trials Methodology Conference, Bristol 2011

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town

Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018

The Open Label Trial Past and Present

The results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain

1. Patterns of disclosure of HIV diagnosis to adolescents/ children: A facility based exploratory study

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

Hormonal Contraception Use and Non-AIDSdefining

Evidence-based ART adherence. Dr Catherine Orrell Desmond Tutu HIV Foundation 26 November 2012

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

HIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative

Supplementary Appendix

Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz

HIV DRUG RESISTANCE IN AFRICA

AIDS Clinical Trials Group A5316

HHS Public Access Author manuscript Drug Alcohol Depend. Author manuscript; available in PMC 2017 February 01.

3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #

A smart and doable investment

Pediatric Patient Information:

Congress report: XV Congreso Panamericano De Infectología the PROGRESS Study

Lopinavir Hair Concentrations Predict Virological Failure Among Asian Children

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006

How Civil Society can win a better AIDS response for communities in the

Update on PrEP progress: WHO/UNAIDS challenges and actions

Acquired HIV Drug Resistance in children in Asia

Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya

The next generation of ART regimens

When to start: guidelines comparison

DNA Genotyping in HIV Infection

Deborah Kacanek, Konstantia Angelidou, Paige L. Williams, Miriam Chernoff, Kenneth Gadow, Sharon Nachman, The IMPAACT P1055 Study Team

What s New in Acute HIV Infection?

The availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings

Projected Demand for HIV Diagnostic Tests

Purpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa

Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice

Antiviral Therapy 2013; 18: (doi: /IMP2329)

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi

Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

Management of NRTI Resistance

Impact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

Hepatitis B Case Studies

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Clinical and Public Health Policy Implications of Findings that:

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART

Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges

Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

increased efficiency. 27, 20

Scottish Medicines Consortium

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

3 rd International Workshop on Women and HIV January 14 th, 2013

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138

DOI: /hiv British HIV Association HIV Medicine (2014), 15, ORIGINAL RESEARCH

HIV-HBV coinfection in HIV population horizontally infected in early childhood between

HHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 June 01.

Update on progress of MPP sublicensees

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study

PrEP efficacy the evidence

STRIBILD (aka. The Quad Pill)

Optimizing ARV For Women

Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents

Ledipasvir-Sofosbuvir (Harvoni)

MODERN ART FOR AFRICA

Meyer JC, Summers B, Lentsoane PP, Mokoka MV, Nyingwa J, Teffu SM

Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study.

Gaps between Policy and Practice in Managing HIV disease in Asia Pacific

Transcription:

Binge drinking decreases weekend adherence in a RCT from low and middle income countries Raquel B. De Boniᵃ Lu Zhengᵇ, Susan Rosenkranzᵇ, Xin Sunᵇ, Sandra Wagnerᵃ, Beatriz Grinsztejnᵃ, Alberto La Rosaᶜ, Samuel Pierreᵈ, Ann Collierᵉ, Robert Grossᶠ ᵃINI Evandro Chagas /FIOCRUZ, ᵇHarvard School of Public Health, ᶜAsociacion Civil Impacta Salud y Educacion, ᵈCentres Gheskio, ᵉUniversity of Washington, ᶠUniversity of Pennsylvania Perelman School of Medicine

Adherence cart effectiveness relies on adherence Different patterns of adherence (not only averages) Consecutive interruptions may have a greater impact on HIV-RNA than the same number of sporadically missed doses Adherence was consistently lower during weekends compared to weekdays Longitudinal study (US, n=116, FU=12m) Method is a limitation Self-reports may not be accurate to detect subtle differences MEMS costs may restrict duration of its use/use in resource limited settings 2 Genberg et al.aids.2012; Bachhuber et al. JAIDS. 2011

Alcohol Alcohol use is associated with non-adherence Associated with weekend cart gaps exploratory cross-sectional study (n=43) Binge drinking easy to screen, highly prevalent 5 or more drinks in a single occasion (men)/ 4 or more (women) associated with unprotected sex and alcohol dependence Hendershot et al.jaids. 2009; Azar et al. Drug Alcohol Dependen.2010; Chibanda et al.jaids.2014; Kenya et al. AIDS Behav.2013;NIAAA.NIAAA Newsl.2004

Objectives To evaluate 1. if there is a difference in weekday vs. weekend adherence 2. the predictors of this difference 4

Method Secondary analysis of the ACTG 5234 clinical trial Directly observed therapy (mdot) increase adherence in LMIC Brazil, Botswana, Haiti, Peru, South Africa, Uganda, Zambia, and Zimbabwe 257 HIV-infected switching to a second regimen (emtricitabine /tenofovir 200/300 mg once daily and lopinavir /ritonavir 400/100 mg twice a day) No statistical/clinical differences on virological failure were found between treatment arms Gross et al. Lancet HIV. 2015;2(1):e12 e19.

Study Population 255 who have adherence measured through MEMS were included in the present analysis 6

Measures and Definitions Adherence Weekend= Friday, MEMS (MWV Healthcare) on the lopinavir/ritonavir Saturday and Sunday bottle MEMS data was summarized % of prescribed doses taken on weekends % of prescribed doses taken on weekdays For each participant, in 4 successive 12-week period (quarters) Outcome = differences of % doses taken on weekdays and % doses taken on weekends 7

Independent variables Measured at baseline Binge drinking 30 days prior study entry Demographics Sex, age, site location Treatment arm Clinical characteristics years on cart before entry, CD4 count (cells/mm 3 ), viral load (log 10 copies/ml) Substance use 30 days prior study entry Self-perception of health 8

Statistical Analysis Differences between % of doses taken on weekdays and weekends in each quarter Wilcoxon signed rank tests Predictors of the differences between % of doses taken on weekdays and weekends Generalized Estimating Equations (GEE) to account for the repeated measures SAS 9.2 was used to analyze data 9

RESULTS Median (Q1-Q3): % doses taken on weekdays and weekends within quarters Wilcoxon signed rank test = P<0.001 in all quarters

Binge drinking Overall prevalence= 22.3% Binge Drinking Yes No P-Value (N=57) (N=198) Sex Male 43 (75.4%) 84 (42.4%) <.001 (a) Age Mean (s.d.) 37.54 (8.35) 38.95 (10.44) 0.29 (b) Site in Haiti Yes 18 (31.6%) 55 (27.8%) 0.58 (a) Treatment arm mdot 31 (54.4%) 96 (48.5%) 0.43 (a) Years on ART before entry Median (Q1, Q3) 2.97 (1.89, 4.56) 3.17 (2.04, 5.08) 0.22 (c) CD4 Count (cells/mm 3 ) Median (Q1, Q3) 213.50 (112.50, 320.00) 169.5 (89.5, 263.0) 0.16(c) Viral load (log 10 copies/ml) Median (Q1, Q3) 4.23 (3.76, 4.84) 4.29 (3.79, 4.92) 0.53 (c) Any substance use last 30 days Yes 6 (10.5%) 1 (0.5%) <.001 (d) Self-perception of health Excellent, very good, good 48 (84.2%) 145 (73.2%) 0.09 (a) (a) Chi-Square Test (b) T-Test with Unequal Variance (c) Wilcoxon Test (d) Fisher's Exact Test

Univariate analysis Variables with statistically significant association with difference in the percent of doses taken during weekdays and weekends: being male binge drinking in the past 30 days self-perception of health later quarter on study 12

Adjusted Estimates for predictors of difference on %doses taken on weekdays and weekends using GEE

Conclusions Adherence to cart Worse on weekends compared to weekdays in LMIC sample Difference increased over time Important pattern to consider in the new interventions Binge drinking Modifiable determinant of drop-offs in weekend adherence Should be screened among HIV infected individuals 14

Acknowledgments Study participants AIDS Clinical Trials Group (ACTG) ACTG sites, study team members, and site personnel AbbVie Inc. and Gilead Pharmaceuticals, which provided the medications for the A5234 trial 15

Thank you! raqueldeboni@ini.fiocruz.br 16